Next Article in Journal
Micro-Injection Moulding of Poly(vinylpyrrolidone-vinyl acetate) Binary and Ternary Amorphous Solid Dispersions
Next Article in Special Issue
Investigation of Fugitive Aerosols Released into the Environment during High-Flow Therapy
Previous Article in Journal
Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study
Previous Article in Special Issue
Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
Open AccessArticle

Vibrating Mesh Nebulisation of Pro-Antimicrobial Peptides for Use in Cystic Fibrosis

1
Department of Chemistry, Royal College of Surgeons in Ireland (RCSI), 123 St. Stephen’s Green, Dublin 2, Ireland
2
Department of Clinical Microbiology, Royal College of Surgeons in Ireland, RCSI Education & Research Centre, Beaumont Hospital, Beaumont, Dublin 9, Ireland
3
Aerogen Ltd., Galway H91 HE94, Ireland
4
School of Pharmacy, Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 2, Ireland
5
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(5), 239; https://doi.org/10.3390/pharmaceutics11050239
Received: 18 April 2019 / Revised: 12 May 2019 / Accepted: 13 May 2019 / Published: 17 May 2019
(This article belongs to the Special Issue Advances in Pulmonary Drug Delivery)
Background: There has been considerable interest in the use of antimicrobial peptides (AMPs) as antimicrobial therapeutics in many conditions including cystic fibrosis (CF). The aim of this study is to determine if the prodrugs of AMPs (pro-AMPs) can be delivered to the lung by a vibrating mesh nebuliser (VMN) and whether the pro-AMP modification has any effect on delivery. Methods: Physical characteristics of the peptides (AMP and pro-AMP) and antimicrobial activity were compared before and after nebulisation. Droplet size distribution was determined by laser diffraction and cascade impaction. Delivery to a model lung was determined in models of spontaneously-breathing and mechanically-ventilated patients. Results: The physical characteristics and antimicrobial activities were unchanged after nebulisation. Mean droplet size diameters were below 5 μm in both determinations, with the fine particle fraction approximately 67% for both peptides. Approximately 25% of the nominal dose was delivered in the spontaneously-breathing model for both peptides, with higher deliveries observed in the mechanically-ventilated model. Delivery times were approximately 170 s per mL for both peptides and the residual volume in the nebuliser was below 10% in nearly all cases. Conclusions: These results demonstrate that the delivery of (pro-)AMPs to the lung using a VMN is feasible and that the prodrug modification is not detrimental. They support the further development of pro-AMPs as therapeutics in CF. View Full-Text
Keywords: aerosol; antibiotics; antimicrobial peptides; cystic fibrosis; inhalation; peptide drugs; pulmonary drug delivery; prodrugs; vibrating mesh nebuliser aerosol; antibiotics; antimicrobial peptides; cystic fibrosis; inhalation; peptide drugs; pulmonary drug delivery; prodrugs; vibrating mesh nebuliser
Show Figures

Graphical abstract

MDPI and ACS Style

Forde, É.; Kelly, G.; Sweeney, L.; Fitzgerald-Hughes, D.; MacLoughlin, R.; Devocelle, M. Vibrating Mesh Nebulisation of Pro-Antimicrobial Peptides for Use in Cystic Fibrosis. Pharmaceutics 2019, 11, 239.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop